Cargando…

Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report

Many previous intervention studies have used functional magnetic resonance imaging (fMRI) data to predict the antidepressant response of patients with major depressive disorder (MDD); however, practical constraints have limited many of those attempts to small, single centre studies which may not ade...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harris, Jacqueline K., Hassel, Stefanie, Davis, Andrew D., Zamyadi, Mojdeh, Arnott, Stephen R., Milev, Roumen, Lam, Raymond W., Frey, Benicio N., Hall, Geoffrey B., Müller, Daniel J., Rotzinger, Susan, Kennedy, Sidney H., Strother, Stephen C., MacQueen, Glenda M., Greiner, Russell
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421454/ https://www.ncbi.nlm.nih.gov/pubmed/35908308 http://dx.doi.org/10.1016/j.nicl.2022.103120

Ejemplares similares

Reliability of a functional magnetic resonance imaging task of emotional conflict in healthy participants
por: Hassel, Stefanie, et al.
Publicado: (2019)

Exploring brain connectivity changes in major depressive disorder using functional‐structural data fusion: A CAN‐BIND‐1 study
por: Ayyash, Sondos, et al.
Publicado: (2021)

An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report
por: Suh, Jee Su, et al.
Publicado: (2020)

Multisite Comparison of MRI Defacing Software Across Multiple Cohorts
por: Theyers, Athena E., et al.
Publicado: (2021)

Magnetic Resonance Imaging Sequence Identification Using a Metadata Learning Approach
por: Liang, Shuai, et al.
Publicado: (2021)

Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report
por: Yrondi, Antoine, et al.
Publicado: (2021)

Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report
por: Yrondi, Antoine, et al.
Publicado: (2019)

Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report
por: Caspani, Giorgia, et al.
Publicado: (2021)

Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report
por: Ballester, Pedro L., et al.
Publicado: (2021)

Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression
por: Zhdanov, Andrey, et al.
Publicado: (2020)

Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response
por: Fiori, Laura M., et al.
Publicado: (2021)

Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study
por: Islam, Farhana, et al.
Publicado: (2022)

Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy
por: Espinola, Caroline W., et al.
Publicado: (2022)

Prediction of depression treatment outcome from multimodal data: a CAN-BIND-1 report
por: Sajjadian, Mehri, et al.
Publicado: (2023)

A detailed manual segmentation procedure for the hypothalamus for 3T T1-weighted MRI
por: Ali, Mohammad, et al.
Publicado: (2022)

Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants
por: Ju, Chelsey, et al.
Publicado: (2019)

Response of Depression to Botulinum Toxin Treatment: Agitation as a Predictor
por: Milev, Roumen
Publicado: (2015)

Resting-state EEG delta and alpha power predict response to cognitive behavioral therapy in depression: a Canadian biomarker integration network for depression study
por: Schwartzmann, Benjamin, et al.
Publicado: (2023)

Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient
por: Oluboka, Oloruntoba J, et al.
Publicado: (2017)

Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant Medication
por: Schwartzmann, Benjamin, et al.
Publicado: (2023)

Gray matter volume drives the brain age gap in schizophrenia: a SHAP study
por: Ballester, Pedro L., et al.
Publicado: (2023)

Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1
por: Nunez, John-Jose, et al.
Publicado: (2021)

The Differential Relation of Emotional, Physical, and Sexual Abuse Histories to Antidepressant Treatment Remission and Persistence of Anhedonia in Major Depression: A CAN-BIND-1 Report
por: Harkness, Kate L., et al.
Publicado: (2023)

Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort
por: Lam, Raymond W., et al.
Publicado: (2016)

MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes
por: Lopez, Juan Pablo, et al.
Publicado: (2017)

Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder
por: Martens, Marieke A. G., et al.
Publicado: (2021)

Pro-inflammatory markers predict response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report
por: Husain, M. I., et al.
Publicado: (2023)

Intrinsic thalamocortical connectivity varies in the age of onset subtypes in major depressive disorder
por: Brown, Elliot C, et al.
Publicado: (2018)

“One Degree of Separation”: A Mixed-Methods Evaluation of Canadian Mental Health Care User and Provider Experiences With Remote Care During COVID-19
por: Ceniti, Amanda K., et al.
Publicado: (2022)

Characterization of gut microbiome in mice model of depression with divergent response to escitalopram treatment
por: Duan, Jiajia, et al.
Publicado: (2021)

Youth at-risk for serious mental illness: methods of the PROCAN study
por: Addington, Jean, et al.
Publicado: (2018)

Resistant social anxiety disorder response to Escitalopram
por: Pallanti, Stefano, et al.
Publicado: (2006)

Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response
por: Marshe, Victoria S., et al.
Publicado: (2021)

Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression
por: Farzan, Faranak, et al.
Publicado: (2017)

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder
por: Yatham, Lakshmi N, et al.
Publicado: (2018)

A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol
por: Phillips, Jennifer L., et al.
Publicado: (2020)

The therapeutic potential of escitalopram in the treatment of panic disorder
por: Townsend, Mark H, et al.
Publicado: (2007)

Short-term escitalopram treatment and hippocampal volume
por: Godlewska, Beata R., et al.
Publicado: (2014)

Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
por: Shao, Shichuan, et al.
Publicado: (2022)

Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults
por: Polychroniou, Philip E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9k9s2lc7ivrufc6l7c9ksmflsu